Skip to main content

Table 1 Patient and tumor characteristics per study arm 1 and in the total study population

From: Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

 

Arm A: E-T-CMF N = 333

Arm B: E-CMF-wD N = 331

Arm C: E-CMF-wT N = 326

Total study population N = 990

Age

    

  Median (range)

53 (28-79)

53 (21-78)

54 (23-78)

53 (21-79)

 

N (%)

N (%)

N (%)

N (%)

Menopausal status

    

  Premenopausal

155 (46.5)

157 (47.4)

149 (45.7)

461 (46.6)

  Postmenopausal

178 (53.5)

174 (52.6)

177 (54.3)

529 (53.4)

Surgery

    

  MRM

167 (50.2)

163 (49.2)

175 (53.7)

505 (51.0)

  Partial mastectomy

166 (49.8)

168 (50.8)

151 (46.3)

485 (49.0)

Tumor size

    

  ≤2

159 (47.7)

139 (42.0)

119 (36.5)

417 (42.1)

  2.1-5

155 (46.5)

169 (51.1)

183 (56.1)

507 (51.2)

  >5

19 (5.7)

23 (6.9)

24 (7.4)

66 (6.7)

Positive nodes

    

  0

83 (24.9)

80 (24.2)

83 (25.5)

246 (24.8)

  1-3

136 (40.8)

136 (41.1)

136 (41.7)

408 (41.2)

  ≥4

114 (34.2)

115 (34.7)

107 (32.8)

336 (33.9)

Histological grade

    

  1

25 (7.5)

16 (4.8)

20 (6.1)

61 (6.2)

  2

155 (46.5)

141 (42.6)

152 (46.6)

448 (45.3)

  3

153 (45.9)

174 (52.6)

154 (47.2)

481 (48.6)

Histological type

    

  Invasive ductal NOS

274 (82.3)

273 (82.5)

279 (85.6)

826 (83.4)

  Invasive lobular

31 (9.3)

28 (8.5)

22 (6.7)

81 (8.2)

  Mixed type

18 (5.4)

18 (5.4)

11 (3.4)

47 (4.7)

  Medullary

6 (1.8)

6 (1.8)

4 (1.2)

16 (1.6)

  Mucinous

2 (0.6)

1 (0.3)

2 (0.6)

5 (0.5)

  Papillary

1 (0.3)

3 (0.9)

3 (0.9)

7 (0.7)

  Tubular

-

-

1 (0.3)

1 (0.1)

  Apocrine

-

1 (0.3)

1 (0.3)

2 (0.2)

  Metaplastic

-

1 (0.3)

-

1 (0.1)

  Neuroendocrine

-

-

1 (0.3)

1 (0.1)

  Myeloepithelioma

-

-

1 (0.3)

1 (0.1)

  Other

1 (0.3)

-

1 (0.3)

2 (0.2)

Hormone receptor status

    

  Negative

74 (22.2)

74 (22.4)

71 (21.8)

219 (22.1)

  Positive

259 (77.8)

257 (77.6)

255 (78.2)

771 (77.9)

HER2 overexpression

    

  No

239 (71.8)

240 (72.5)

237 (72.7)

716 (72.3)

  Yes

94 (28.2)

91 (27.5)

89 (27.3)

274 (27.7)

Triple-negative

    

  No

292 (87.7)

288 (87.0)

291 (89.3)

871 (88.0)

  Yes

41 (12.3)

43 (13.0)

35 (10.7)

119 (12.0)

Post-chemotherapy treatment

    

  Adjuvant hormonal therapy

    

     No

83 (24.9)

85 (25.7)

83 (25.5)

251 (25.4)

     Yes

250 (74.1)

246 (74.3)

243 (74.5)

739 (74.6)

       Tamoxifen

122 (36.6)

113 (34.1)

105 (32.2)

340 (34.3)

       LH-RH

101 (30.3)

94 (28.4)

97 (29.8)

292 (29.5)

       Aromatase inhibitor

150 (45.0)

152 (45.9)

163 (50.0)

465 (47.0)

       Fulvestrant

1 (0.3)

1 (0.3)

1 (0.3)

3 (0.3)

  Adjuvant radiotherapy

    

     No

89 (26.7)

95 (28.7)

89 (27.3)

273 (27.6)

     Yes

244 (73.3)

236 (71.3)

237 (72.7)

717 (72.4)

  Trastuzumab treatment

    

     No

243 (73.0)

247 (74.6)

245 (75.2)

735 (74.2)

     Yes

90 (27.0)

84 (25.4)

81 (24.8)

255 (25.8)

  1. 1No significant differences between treatment arms were found (Pearson chi-square test).
  2. N number of patients, MRM modified radical mastectomy, NOS not otherwise specified.